---
url: https://endpoints.news/alumis-tyk2-drug-succeeds-in-key-psoriasis-studies-will-seek-fda-approval/?u=786c1a58-a68e-4805-8b2a-95166d105077&s=email&c=79153abc-2ae9b617-49f4c1b2&utm_medium=email&utm_campaign=2360%20-%20The%20first%20biotech%20acquisition%20of%202026%20Protagonists%20Robin%20Hood%20plan%20Insider&utm_content=2360%20-%20The%20first%20biotech%20acquisition%20of%202026%20Protagonists%20Robin%20Hood%20plan%20Insider+CID_7588dbc49a6260cbb1094a197d9a120c&utm_source=ENDPOINTS%20emails&utm_term=Alumis%20TYK2%20drug%20succeeds%20in%20key%20psoriasis%20studies%20will%20seek%20FDA%20approval
title: "Alumis’ TYK2 drug succeeds in key psoriasis studies, will seek FDA approval"
clipped: 2026-01-06 12:16
source: browser-history
---

# Alumis’ TYK2 drug succeeds in key psoriasis studies, will seek FDA approval

> Source: [https://endpoints.news/alumis-tyk2-drug-succeeds-in-key-psoriasis-studies-will-seek-fda-approval/?u=786c1a58-a68e-4805-8b2a-95166d105077&s=email&c=79153abc-2ae9b617-49f4c1b2&utm_medium=email&utm_campaign=2360%20-%20The%20first%20biotech%20acquisition%20of%202026%20Protagonists%20Robin%20Hood%20plan%20Insider&utm_content=2360%20-%20The%20first%20biotech%20acquisition%20of%202026%20Protagonists%20Robin%20Hood%20plan%20Insider+CID_7588dbc49a6260cbb1094a197d9a120c&utm_source=ENDPOINTS%20emails&utm_term=Alumis%20TYK2%20drug%20succeeds%20in%20key%20psoriasis%20studies%20will%20seek%20FDA%20approval](https://endpoints.news/alumis-tyk2-drug-succeeds-in-key-psoriasis-studies-will-seek-fda-approval/?u=786c1a58-a68e-4805-8b2a-95166d105077&s=email&c=79153abc-2ae9b617-49f4c1b2&utm_medium=email&utm_campaign=2360%20-%20The%20first%20biotech%20acquisition%20of%202026%20Protagonists%20Robin%20Hood%20plan%20Insider&utm_content=2360%20-%20The%20first%20biotech%20acquisition%20of%202026%20Protagonists%20Robin%20Hood%20plan%20Insider+CID_7588dbc49a6260cbb1094a197d9a120c&utm_source=ENDPOINTS%20emails&utm_term=Alumis%20TYK2%20drug%20succeeds%20in%20key%20psoriasis%20studies%20will%20seek%20FDA%20approval)

![](https://endpoints.news/wp-content/uploads/2024/03/Martin-Babler-Alumis-feature.jpg)

Martin Babler, Alumis CEO

January 6, 2026 11:22 AM EST

[R&D](https://endpoints.news/channel/rd/ "Channel: R&D")

# Alu­mis' TYK2 drug suc­ceeds in key pso­ri­a­sis stud­ies, will seek FDA ap­proval

### [Lei Lei Wu](https://endpoints.news/author/lei-lei-wu/ "See all stories by Lei Lei Wu")

#### News Reporter

Alu­mis re­port­ed its ex­per­i­men­tal pill helped clear skin symp­toms from pso­ri­a­sis across two Phase 3 tri­als, trig­ger­ing a surge in the Bay Area biotech’s stock …

![Endpoints News](https://endpoints.news/wp-content/themes/endpoints-rakia/assets/svg/epn_logo.svg)

### Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

[SIGN UP](https://profile.endpoints.news/sso?mode=sign-up&r=https%3A%2F%2Fendpoints.news%2Fauth&a%5Bt%5D=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%3D%3D)
[LOG IN](https://profile.endpoints.news/sso?r=https%3A%2F%2Fendpoints.news%2Fauth&a%5Bt%5D=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%3D%3D)
[BECOME A PREMIUM SUBSCRIBER](https://profile.endpoints.news/upgrade)